
Calibrating real-world evidence studies against randomised trials
17 May 2022
- Real-world evidence (RWE) on the effectiveness of treatments in Crohn’s disease (CD) derived from clinical practice data will help fill many evidence gaps left by randomized controlled trials (RCTs)
- Using claims data (2004–2019) from commercially insured patients in the United States (IBM MarketScan and Optum) and France (Système National des Données de Santé (National Healthcare Data System) (SNDS)), a cohort study of patients with CD who initiated combination therapy were compared with patients who initiated infliximab alone
- These robust findings highlight opportunities in RWE analysis for studying treatment effectiveness in patients with CD in clinical practice